Journal of Microbiology and Biotechnology

  • 제31권3호
  • /
  • Pages.380-386
  • /
  • 2021
  • /
  • 1017-7825(pISSN)
  • /
  • 1738-8872(eISSN)
한국미생물·생명공학회 (The Korean Society for Microbiology and Biotechnology)
권호 표지
DOI QR코드

DOI QR Code

Clinical Effect of Traditional Chinese Medicine Shenhuang Granule in Critically Ill Patients with COVID-19: A Single-Centered, Retrospective, Observational Study

  • Feng, Jun (Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Fang, Bangjiang (Department of Emergency Medicine, LongHua Hospital, Shanghai University of Traditional Chinese Medicine) ;
  • Zhou, Daixing (Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Wang, Junshuai (Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Zou, Dengxiu (Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Yu, Gang (Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Fen, Yikuan (Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Peng, Dan (Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Hu, Jifa (Office of Academic Research, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) ;
  • Zhan, Daqian (Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology)
  • 투고 : 2020.09.16
  • 심사 : 2021.02.06
  • 발행 : 2021.03.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The coronavirus disease 2019 (COVID-19) pandemic has become a public health emergency of global concern. In China, traditional Chinese medicine has been widely administered to COVID-19 patients without sufficient evidence. To evaluate the efficacy of Shenhuang Granule (SHG) for treating critically ill patients with COVID-19, we included in this study 118 patients who were admitted to the ICU of Tongji Hospital between January 28, 2020 and March 28, 2020. Among these patients, 33 (27.9%) received standard care plus SHG (treatment group) and 85 (72.1%) received standard care alone (control group). Enrolled patients had a median (IQR) age of 68 (57-75) years, and most (79 [67.1%]) were men. At end point of this study, 83 (70.3%) had died in ICU, 29 (24.5%) had been discharged from ICU, and 6 patients (5.2%) were still in ICU. Compared with control group, mortality was significantly lower in treatment group (45.4% vs. 80%, p < .001). Patients in treatment group were less likely to develop acute respiratory distress syndrome (ARDS) (12 [36.3%] vs. 54 [63.5%], p = 0.012) and cardiac injury (5 [15.1%] vs. 32 [37.6%], p = 0.026), and less likely to receive mechanical ventilation (22 [66.7%] vs. 72 [84.7%], p = 0.028) than those in control group. The median time from ICU admission to discharge was shorter in treatment group (32 [20-73] days vs. 76 [63-79] days, p = 0.0074). These findings suggest that SHG treatment as a complementary therapy might be effective for critically ill adults with COVID-19 and warrant further clinical trials.

키워드

참고문헌

  1. Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. 2020. The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. J. Clin. Med. 9: 1225. https://doi.org/10.3390/jcm9041225
  2. Weiss P, Murdoch DR. 2020. Clinical course and mortality risk of severe COVID-19. Lancet 395: 1014-1015. https://doi.org/10.1016/s0140-6736(20)30633-4
  3. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. 2020. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 180: 934-943 https://doi.org/10.1001/jamainternmed.2020.0994
  4. Onder G, Rezza G, Brusaferro S. 2020. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 323: 1775-1776.
  5. Poston JT, Patel BK, Davis AM. 2020. Management of critically ill adults with COVID-19. JAMA 323: 1839-1841.
  6. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382: 1787-1799. https://doi.org/10.1056/NEJMoa2001282
  7. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. 2020. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N. Engl. J. Med. 382: 2411-2418. https://doi.org/10.1056/NEJMoa2012410
  8. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. 2020. Treatment of 5 critically III patients with COVID-19 with convalescent plasma. JAMA 323:1582-1589. https://doi.org/10.1001/jama.2020.4783
  9. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. 2020. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA
  10. Yang Y, Islam MS, Wang J, Li Y, Chen X. 2020. Traditional Chinese medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective. Int. J. Biol. Sci. 16: 1708-1717. https://doi.org/10.7150/ijbs.45538
  11. Zhang W, Fang BJ, Wang G. 2020.The basic theory and practical application of catharsis large intestine and truncating and reversing in the prevention and treatment of sepsis. CJITWM 40: 102-5. https://doi.org/10.7661/j.cjim.20191009.224.
  12. Fang BJ, Zhang W, Wu XX, Huang TR, Li HC, Zheng Y, et al. 2020. Shenhuang granule in the treatment of severe coronavirus disease 2019 (COVID-19): study protocol for an open-label randomized controlled clinical trial. Trials 21: 568. https://doi.org/10.1186/s13063-020-04498-6
  13. Fang BJ, Sun LH, Bu JH. 2017. The discussion of acute deficiency syndrome theory and its clinical application in emergency medicine. JETCM 26: 1724-1726. https://doi.org/10.3969/j.issn.1004-745X.2017.10.010.
  14. Xi XT, Zeng RF, Li J. 2018. The new thinking of integrated traditional Chinese and Western medicine from the core pathogenesis of sepsis. JETCM 27: 105-109. doi:https://doi.org/10.3969/j.issn.1004-745X.2018.1.032.
  15. Wang Y, Jung Y-J, Kim K-H, Kwon Y, Kim Y-J, Zhang Z, et al. 2018. Antiviral activity of fermented ginseng extracts against a broad range of influenza viruses. Viruses 10: 471. https://doi.org/10.3390/v10090471
  16. Gao J, Zhang JZ, Zhang PT. 2002. Clinical research on impact of jinhong decoction on sepsis. Acad. J. Shanghai Univ. Tradit. Chin. Med. 16: 43-44.
  17. Zhu PT, Zhang JZ, Gao J, Xl Z, Wang ZG, Shen P, et al. 2001. Experimental study on "Jinhong Pill" in regulating cytokine and preventing intestinal mucosal barrier of acute biliary tract infection in rats. Shanghai J. Tradit. Chin. Med. 4: 39-42.
  18. Xie YF, Feng WW, Liu MC, Xie J, Yu L, Gong XH, et al. 2019. Investigation of efficacy enhancing and toxicity reducing mechanism of combination of aconiti lateralis radix praeparata and paeoniae radix alba in adjuvant-induced arthritis rats by metabolomics. Evid. Based Complement. Alternat. Med. 2019: 9864841.
  19. Li SS, Cheng L, An DK, Song SL, Liang H, Chu FL, et al. 2017. Whitmania pigra whitman extracts inhibit lipopolysaccharide induced rat vascular smooth muscle cells migration and their adhesion ability to THP-1 and RAW 264.7 cells. J. Atheroscler. Thromb. 24: 301-311. https://doi.org/10.5551/jat.36558
  20. Force ADT, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, et al. 2012. Acute respiratory distress syndrome: the Berlin Definition. JAMA 307: 2526-2533.
  21. Khwaja A. 2012. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin. Pract. 120: c179-184. https://doi.org/10.1159/000339789
  22. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. 2020. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55: 102763. https://doi.org/10.1016/j.ebiom.2020.102763
  23. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. 2020. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8: 475-481. https://doi.org/10.1016/s2213-2600(20)30079-5
  24. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054-1062. https://doi.org/10.1016/s0140-6736(20)30566-3
  25. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. 2020. Covid-19 in Critically III Patients in the Seattle Region - Case Series. N. Engl. J. Med. 382: 2012-2022. https://doi.org/10.1056/NEJMoa2004500
  26. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497-506. https://doi.org/10.1016/s0140-6736(20)30183-5
  27. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. 2020. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395: 1033-1034. https://doi.org/10.1016/s0140-6736(20)30628-0
  28. Dhama K, Patel SK, Pathak M, Yatoo MI, Tiwari R, Malik YS, et al. 2020. An update on SARS-CoV-2/COVID-19 with particular reference to its clinical pathology, pathogenesis, immunopathology and mitigation strategies. Travel Med. Infect. Dis. 37: 101755. https://doi.org/10.1016/j.tmaid.2020.101755
  29. Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. 2007. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 74: 92-101. https://doi.org/10.1016/j.antiviral.2006.04.014
  30. Chen W, Lim CE, Kang HJ, Liu J. 2011. Chinese herbal medicines for the treatment of type A H1N1 influenza: a systematic review of randomized controlled trials. PLoS One. 6: e28093. https://doi.org/10.1371/journal.pone.0028093
  31. Liu J, Manheimer E, Shi Y, Gluud C. 2004. Chinese herbal medicine for severe acute respiratory syndrome: a systematic review and meta-analysis. J. Altern. Complement. Med. 10: 1041-1051. https://doi.org/10.1089/acm.2004.10.1041
  32. Zhang QH, Wu CF, Duan L, Yang JY. 2008. Protective effects of total saponins from stem and leaf of Panax ginseng against cyclophosphamide-induced genotoxicity and apoptosis in mouse bone marrow cells and peripheral lymphocyte cells. Food Chem. Toxicol. 46: 293-302. https://doi.org/10.1016/j.fct.2007.08.025
  33. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. 2020. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J. Clin. Virol. 127: 104370. https://doi.org/10.1016/j.jcv.2020.104370

피인용 문헌

  1. Efficacy and Safety of Traditional Chinese Medicine in Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis vol.12, 2021, https://doi.org/10.3389/fphar.2021.609213